Evofem Biosciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Evofem Biosciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 22.8% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evofem Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 18 | 50 | -9 | -9 | N/A |
9/30/2023 | 14 | 44 | -15 | -15 | N/A |
6/30/2023 | 15 | 67 | -29 | -29 | N/A |
3/31/2023 | 18 | -48 | -55 | -54 | N/A |
12/31/2022 | 17 | -78 | -71 | -70 | N/A |
9/30/2022 | 20 | -119 | -86 | -85 | N/A |
6/30/2022 | 16 | -283 | -107 | -106 | N/A |
3/31/2022 | 11 | -192 | -135 | -133 | N/A |
12/31/2021 | 8 | -206 | -150 | -147 | N/A |
9/30/2021 | 5 | -194 | -169 | -164 | N/A |
6/30/2021 | 3 | -150 | -167 | -163 | N/A |
3/31/2021 | 2 | -169 | -128 | -124 | N/A |
12/31/2020 | 0 | -142 | -107 | -105 | N/A |
9/30/2020 | 0 | -114 | -80 | -79 | N/A |
6/30/2020 | N/A | -98 | -58 | -58 | N/A |
3/31/2020 | N/A | -81 | -63 | -62 | N/A |
12/31/2019 | N/A | -80 | -55 | -55 | N/A |
9/30/2019 | N/A | -82 | -52 | -52 | N/A |
6/30/2019 | N/A | -87 | -46 | -46 | N/A |
3/31/2019 | N/A | -75 | -46 | -46 | N/A |
12/31/2018 | N/A | -126 | -57 | -56 | N/A |
9/30/2018 | N/A | -131 | -51 | -51 | N/A |
6/30/2018 | N/A | -188 | -47 | -47 | N/A |
3/31/2018 | N/A | -172 | -31 | -31 | N/A |
12/31/2017 | N/A | -109 | -19 | -19 | N/A |
9/30/2017 | N/A | -103 | N/A | -20 | N/A |
12/31/2016 | N/A | -69 | N/A | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if EVFM's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if EVFM's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if EVFM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if EVFM's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if EVFM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EVFM's Return on Equity is forecast to be high in 3 years time